Nationwide Long-Term Survey of Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drugs to Establish the Therapeutic Strategy to Prevent Severe Liver Injury.

Nationwide Long-Term Survey of Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drugs to Establish the Therapeutic Strategy to Prevent Severe Liver Injury. - Long-Term Survey of Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drugs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008875

Enrollment

500

Registered

2012-09-07

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-infected patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with previous HBV infection receiving immunosuppresive therapies

Exclusion criteria

Exclusion criteria: Patients receiving rituximab

Design outcomes

Primary

Measure	Time frame
To clarrify the prevalence of HBV-reactivation depending on the types of disease and therapies.	—

Countries

Japan

Contacts

Public ContactNobuaki Nakayama

Saitama Medical University Department of Gastroenterology and Hepatology

kgoto@saitama-med.ac.jp049-276-1198

Outcome results